Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 8Recruiting 3Terminated 2Not yet recruiting 2Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Neoplasm, Residual 2Leukemia 2Burkitt Lymphoma 2Myasthenia Gravis 1Leukemia, Myeloid 1Leukemia, Lymphoid 1Graft vs Host Disease 1

Interventions

venetoclax 4Cyclophosphamide 4fludarabine 3Azacitidine 3blinatumomab 2Whole-Body Irradiation 2Cytarabine 2Blood Specimen Collection 2pegaspargase 1etoposide phosphate 1capivasertib 1Vincristine 1Tretinoin 1Tissue Banks 1Tacrolimus 1Mycophenolic Acid 1Methotrexate 1Mercaptopurine 1Immunotherapy, Adoptive 1IPI-549 1Etoposide 1Drug Therapy, Combination 1Doxorubicin 1Dexamethasone 1Decitabine 1Calcium Dobesilate 1Busulfan 1Arsenic Trioxide 1Anthracyclines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Leukemia × blinatumomab × Clear all
NCT07227584 2025-11-12

ALL Backbone in AYAs

Dana-Farber Cancer Institute

Phase 2 Not yet recruiting
67 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06649422 2024-10-18

Reduced-Dose Chemo Followed by 14 Days of Blinatumomab for Newly Diagnosed Adult B-ALL Patients: a Multicenter Study

Shandong University

Not yet recruiting
36 enrolled
Other hematologic neoplasm

Leukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡